

Please try another search
Investing.com - United Therapeutics (NASDAQ: UTHR) reported first quarter EPS of $4.86, $0.32 better than the analyst estimate of $4.54. Revenue for the quarter came in at $506.9M versus the consensus...
Investing.com - United Therapeutics (NASDAQ: UTHR) reported fourth quarter EPS of $2.67, $2.05 worse than the analyst estimate of $4.72. Revenue for the quarter came in at $491.5M versus the consensus...
United Therapeutics (NASDAQ:UTHR) reported Q4 EPS of $2.67, $2.05 worse than the analyst estimate of $4.72. Revenue for the quarter came in at $491.5 million versus the consensus estimate of $519.21...
United Therapeutics (UTHR) reported Q3 EPS of $4.91, $0.85 better than the analyst estimate of $4.06. Revenue for the quarter came in at $516 million versus the consensus estimate of $493.81 million.
Investing.com - United Therapeutics (NASDAQ:UTHR) reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. United Therapeutics announced...
By Sam Boughedda Liquidia Technologies Inc (NASDAQ:LQDA) shares have tumbled Tuesday, down 27% at the time of writing, after a decision from the U.S. District Court denying its request to stay a...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review